Aurobindo Pharma Q2FY19E Result Expectation

Aurobindo Pharma is expected to report a 5.7% yoy revenue growth over new product launches; profitability is likely to remain weak due to high base. 

• Consensus estimates for Q2FY19 
• Revenue – Rs4,691cr, up 5.7% yoy, due to weak currency, lower base price erosion, and market share gain in gIbuprofen, gReyataz and gErtapenem. 
• EBITDA – Expected to decline 11.6% yoy to Rs988cr due to high base; EBITDA margin expected at 21.1% PAT - Expected to decline 17.3% yoy to Rs606cr 

Q1FY19 performance highlights 

• Revenue – Rs4,250.3cr grew 15.5% yoy 
• EBITDA – Rs711.1cr, declined 14.7% yoy, margins stood at 16.7% 
• PAT – Rs455.7cr, yoy decline of 12.1%

To Get Free Trial 
Missed call @ 8817002233 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php